Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
SHPH - Shuttle Pharmaceuticals Holding
Market Cap 12.43M P/E - EPS this Y - Ern Qtrly Grth -
Income -7.2M Forward P/E - EPS next Y - 50D Avg Chg -16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book 1.78 EPS next 5Y - 52W High Chg -99.00%
Recommedations - Quick Ratio 1.69 Shares Outstanding 2.95M 52W Low Chg 8.00%
Insider Own 41.62% ROA -61.69% Shares Float 1.36M Beta 1.04
Inst Own 1.73% ROE -186.00% Shares Shorted/Prior 85.80K/20.80K Price 0.90
Gross Margin - Profit Margin - Avg. Volume 1,508,429 Target Price -
Oper. Margin - Earnings Date - Volume 66,192 Change -1.09%
Healthcare | Drug Manufacturers - Specialty & Generic | United States
About Shuttle Pharmaceuticals Holding

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Shuttle Pharmaceuticals Holding News
12/19/24 Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
11/26/24 Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
11/13/24 Shuttle Pharma Provides Third Quarter 2024 Corporate Update
10/29/24 Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
10/29/24 Shuttle Pharma Pays Off Senior Secured Convertible Note
10/29/24 Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28/24 Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28/24 Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
09/16/24 Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
09/11/24 Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
09/05/24 Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
09/04/24 Shuttle Pharma Provides Second Quarter 2024 Corporate Update
08/28/24 Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
08/26/24 Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
08/14/24 Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
07/19/24 Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
06/18/24 Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
03:15 PM Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
05/14/24 Shuttle Pharma Provides First Quarter 2024 Corporate Update
04/29/24 Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Brown Milton Director Director Dec 13 Sell 0.4632 2,921 1,353 1,094,610 01/02/24
Jacobs Bette Director Director Dec 13 Sell 0.4632 4,157 1,926 27,064 12/20/23
Dritschilo Anatoly CEO and Chairman CEO and Chairman Dec 29 Sell 1.605 8,372 13,437 1,085,200 01/03/23
Rich Tyvin Chief Medical Office.. Chief Medical Officer Dec 29 Sell 1.605 1,414 2,269 2,429 01/03/23
Jung Mira Chief Scientific Off.. Chief Scientific Officer Dec 29 Sell 1.605 328 526 1,071,388 01/03/23
Jacobs Bette Director Director Dec 29 Sell 1.605 4,366 7,007 31,221 01/03/23
Dritschilo Peter President and COO President and COO Dec 29 Sell 1.605 3,820 6,131 6,560 12/30/22